All Therapeutics articles – Page 8
-
NewsKeytruda post-surgery could halt return of distant tumours in rare skin cancer
Merck & Co’s anti-PD-1 immunotherapy showed evidence at ESMO of its ability to prevent cancer recurrence in Merkel cell carcinoma.
-
WebinarAutomating quality control testing for radiopharmaceutical production
This webinar showcased a rapid microbial method that can help to address the time to result challenge posed by short shelf-life radiopharmaceuticals.
-
NewsNovel topical formulation demonstrates potential in peripheral neuropathy
Offers potential symptomatic relief for cancer patients with chemotherapy-induced peripheral neuropathy (CIPN).
-
NewsTakeda withdraws from clinical cell therapy activities
The company will instead focus its attention on advancing candidates for modalities that include biologics and ADCs.
-
NewsAI adoption in life science labs faces a growing skills barrier
Pistoia Alliance survey also found that the greatest benefit for lab digitalisation has shifted from efficiency to innovation.
-
NewsCall for greater investment and innovation from pharma to address RSV
Despite progress from AstraZeneca, Sanofi, Merck & Co, GSK and Pfizer, analysts say effective respiratory syncytial virus treatments are still needed.
-
NewsJ&J’s Tremfya secures two paediatric psoriasis approvals from FDA
The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.
-
NewsGenmab makes $8bn acquisition to boost late-stage antibody therapy pipeline
The deal will support the biotech in its plans to advance bispecific antibody petosemtamab in multiple oncology indications.
-
ArticleNavigating evolving clinical and regulatory expectations as mRNA outgrows its vaccine roots
Jianbo Diao, PhD, Director of Bioanalytical Services, WuXi AppTec, discusses the importance for mRNA therapy developers of adopting precise and flexible analytical strategies for future pipeline success.
-
NewsLilly wins European Alzheimer’s approval for Kisunla after regulatory setbacks
The anti-amyloid monoclonal antibody is part of the class of medicines representing the first disease-modifying therapies for the neurodegenerative disease.
-
NewsOne-time gene therapy could “transform” Huntington’s treatment landscape
uniQure’s positive topline data “are the most convincing in the field to date” and indicate the gene therapy’s potential disease-modifying effects.
-
NewsNovel analytical approach could aid quality control during nitrosamine analysis
The innovative approach facilitates QSRR-assisted chromatographic development for N-nitrosamine analysis in pharmaceutical products.
-
NewsLilly to site next US manufacturing facility in Texas
The new $6.5 billion Houston site will manufacture active pharmaceutical ingredients (APIs) in support of the company’s pipeline of small molecule medicines.
-
NewsBayer claims cell and gene therapy first in Parkinson’s research
Advances cell therapy and gene therapy candidates, with both showing neurorestorative potential against the disease.
-
NewsNovo Nordisk’s once-weekly diabetes jab Kyinsu set for European approval
EMA advisors at the CHMP backed the combination treatment and also recommended Bayer’s menopause drug Lynkuet, putting both on the path to being licensed.
-
ArticleValidation data for the new MAS-100 Sirius
In this App Note, MBV AG showcases the MAS-100 Sirius as the advanced successor to the MAS-100 NT, offering significantly enhanced capabilities for quantitative monitoring of airborne viable particles in cleanrooms.
-
ArticleSimplified rAAV lysate purification for complex analytics of upstream samples
Bioprocess experts from Sartorius BIA Separations and BridgeBio Gene Therapy illustrate an approach with potential to expedite AAV upstream analytics and lower overall process development costs.
-
ArticleMicrobiology/RMM In-Depth Focus 2025
This in-depth focus features articles on rapid microbiological methods, quality control, and using AI to read agar plates.
-
ArticleDrug development In-Depth Focus 2025
From groundbreaking cell and gene therapies to cost-effective drug delivery innovations, Europe is emerging as a hub for life-changing therapies. Explore expert insights and innovative solutions shaping the pharmaceutical industry.
-
ArticleGuide to Outsourcing 2025
Doug Botkin, PhD Scientific Portfolio Specialist from Charles River Laboratories, examines how modern microbial ID tools can enhance contamination control strategies and the benefits an outsourcing partner can provide.